# T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

> **NCT00433407** · NA · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer
- Lung Cancer
- Ovarian Cancer
- Prostate Cancer
- Sarcoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** trastuzumab

## Key facts

- **NCT ID:** NCT00433407
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00433407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00433407, "T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00433407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*